OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 03:45:02 2024-06-27 pm EDT | ||
| 24.17 EUR | +0.25% |
|
| Current month | +8.43% | ||
| 1 month | +7.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 24.17 | +0.25% |
| 24-06-26 | 24.11 | +0.79% |
| 24-06-25 | 23.92 | -1.12% |
| 24-06-24 | 24.19 | +1.64% |
| 24-06-21 | 23.8 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF90MD |
| ISIN | DE000SF90MD6 |
| Date issued | 2021-12-03 |
| Strike | 216 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.55 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.05 € |
|---|---|
| Lowest since issue | 2.49 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
472.5
USD
Average target price
468.3
USD
Spread / Average Target
-0.90%
- Stock Market
- Certificates
- Certificat
